The persistency of high levels of pSTAT3 expression in circulating CD4+ T cells from CIS patients favors the early conversion to clinically defined multiple sclerosis

Journal of Neuroimmunology

Volumn 205, Issue 1-2, 2008, Pages 126-134

  Frisullo, Giovanni ^a   Nociti, Viviana ^a,b   Iorio, Raffaele ^a   Patanella, Agata Katia ^a,b   Marti, Alessandro ^a   Mirabella, Massimiliano ^a   Tonali, Pietro Attilio ^a,b   Batocchi, Anna Paola ^a,b  

^a CATHOLIC UNIVERSITY   (Italy)

^b IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

Author keywords

Clinically isolated syndrome; IFN ; IL17; STAT1; STAT3; T bet

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; STAT1 PROTEIN; STAT3 PROTEIN; TRANSCRIPTION FACTOR T BET;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICALLY ISOLATED SYNDROME; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MALE; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MULTIPLE SCLEROSIS; STAT3 TRANSCRIPTION FACTOR; YOUNG ADULT;

EID: 56349095790     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2008.09.003     Document Type: Article

References (33)

1. Bettelli E., Sullivan B., Szabo S.J., Sobel R.A., Glimcher L.H., and Kuchroo V.K. Loss of T-bet, but not STAT1, prevents the development of experimental autoimmune encephalomyelitis. J. Exp. Med. 200 (2004) 79-87
2. Bettelli E., Korn T., Oukka M., and Kuchroo V.K. Induction and effector functions of T(H)17 cells. Nature 453 7198 (2008) 1051-1057
3. Bielekova B., and Martin R. Development of biomarkers in multiple sclerosis. Brain 127 (2004) 1463-1478
4. Comi G., Filippi M., Barkhof F., Durelli L., Edan G., Fernández O., Hartung H., Seeldrayers P., Sørensen P.S., Rovaris M., Martinelli V., and Hommes O.R. Early Treatment of Multiple Sclerosis Study Group. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 357 (2001) 1576-1582
5. Frisullo G., Angelucci F., Caggiula M., Nociti V., Iorio R., Patanella A.K., Sancricca C., Mirabella M., Tonali P.A., and Batocchi A.P. pSTAT1, pSTAT3, and T-bet expression in peripheral blood mononuclear cells from relapsing-remitting multiple sclerosis patients correlates with disease activity. J. Neurosci. Res. 84 (2006) 1027-1036
6. Hohlfeld R., and Wekerle H. Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy from pipe dreams to (therapeutic) pipelines. PNAS 101 (2004) 14599-14606
7. Ilangumaran S., Finan D., and Rottapel R. Flow cytometric analysis of cytokine receptor signal transduction. J. Immunol. Methods 278 (2003) 221-234
8. Ivanov I.I., McKenzie B.S., Zhou L., Tadokoro C.E., Lepelley A., Lafaille J.J., Cua D.J., and Littman D.R. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 126 (2006) 1121-1133
9. Kahl K.G., Kruse N., Toyka K.V., and Rieckmann P. Serial analysis of cytokine mRNA profiles in whole blood samples from patients with early multiple sclerosis. J. Neurol. Sci. 200 (2002) 53-55
10. Kappos L., Polman C.H., Freedman M.S., Edan G., Hartung H.P., Miller D.H., Montalban X., Barkhof F., Bauer L., Jakobs P., Pohl C., and Sandbrink R. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 67 (2006) 1242-1249
11. Kappos L., Freedman M.S., Polman C.H., Edan G., Hartung H.P., Miller D.H., Montalbán X., Barkhof F., Radü E.W., Bauer L., Dahms S., Lanius V., Pohl C., and Sandbrink R. BENEFIT Study Group. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 370 (2007) 389-397
12. Kebir H., Kreymborg K., Ifergan I., Dodelet-Devillers A., Cayrol R., Bernard M., Giuliani F., Arbour N., Becher B., and Prat A. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat. Med. 13 (2007) 1173-1175
13. Kinkel R.P., Kollman C., O'Connor P., Murray T.J., Simon J., Arnold D., Bakshi R., Weinstock-Gutman B., Brod S., Cooper J., Duquette P., Eggenberger E., Felton W., Fox R., Freedman M., Galetta S., Goodman A., Guarnaccia J., Hashimoto S., Horowitz S., Javerbaum J., Kasper L., Kaufman M., Kerson L., Mass M., Rammohan K., Reiss M., Rolak L., Rose J., Scott T., Selhorst J., Shin R., Smith C., Stuart W., Thurston S., and Wall M. CHAMPIONS Study Group. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology 66 (2006) 678-684
14. Kivisäkk P., Tian W., Matusevicius D., Link H., and Söderström M. Optic neuritis and cytokines: no relation to MRI abnormalities and oligoclonal bands. Neurology 50 (1998) 217-223
15. Komiyama Y., Nakae S., Matsuki T., Nambu A., Ishigame H., Kakuta S., Sudo K., and Iwakura Y. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J. Immunol. 177 (2006) 566-573
16. Levy D.E., and Lee C.K. What does Stat3 do?. J. Clin. Invest. 109 (2002) 1143-1148
17. Lighvani A.A., Frucht D.M., Jankovic D., Yamane H., Aliberti J., Hissong B.D., Nguyen B.V., Gadina M., Sher A., Paul W.E., and O'Shea J.J. T-bet is rapidly induced by interferon-gamma in lymphoid and myeloid cells. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 15137-15142
18. Link H., and Huang Y.M. Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness. J. Neuroimmunol. 180 (2006) 17-28
19. Link J., Söderström M., Olsson T., Höjeberg B., Ljungdahl A., and Link H. Increased transforming growth factor-beta, interleukin-4, and interferon-gamma in multiple sclerosis. Ann. Neurol. 36 (1994) 379-386
20. Liu X., Lee Y.S., Yu C.R., and Egwuagu C.E. Loss of STAT3 in CD4+ T cells prevents development of experimental autoimmune diseases. J. Immunol. 180 (2008) 6070-6076
21. Martinez-Forero I., Garcia-Munoz R., Martinez-Pasamar S., Inoges S., Lopez-Diaz de Cerio A., Palacios R., Sepulcre J., Moreno B., Gonzalez Z., Fernandez-Diez B., Melero I., Bendandi M., and Villoslada P. IL-10 suppressor activity and ex vivo Tr1 cell function are impaired in multiple sclerosis. Eur. J. Immunol. 38 (2008) 576-586
22. Mathur A.N., Chang H.C., Zisoulis D.G., Stritesky G.L., Yu Q., O'Malley J.T., Kapur R., Levy D.E., Kansas G.S., and Kaplan M.H. Stat3 and Stat4 direct development of IL-17-secreting Th cells. J. Immunol. 178 (2007) 4901-4907
23. McDonald W.I., Compston A., Edan G., Goodkin D., Hartung H.P., Lublin F.D., McFarland H.F., Paty D.W., Polman C.H., Reingold S.C., Sandberg-Wollheim M., Sibley W., Thompson A., van den Noort S., Weinshenker B.Y., and Wolinsky J.S. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann. Neurol. 50 (2001) 121-127
24. Miller D., Barkhof F., Mantalban X., Thompson A., and Filippi M. Clinically isolated syndromes suggestive of multiple sclerosis, part 1: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol. 4 (2005) 281-288
25. Miller D., Barkhof F., Mantalban X., Thompson A., and Filippi M. Clinically isolated syndromes suggestive of multiple sclerosis, part 2: non-conventional MRI, recovery processes, and management. Lancet Neurol. 4 (2005) 341--248
26. Mullen A.C., High F.A., Hutchins A.S., Lee H.W., Villarino A.V., Livingston D.M., Kung A.L., Cereb N., Yao T.P., Yang S.Y., and Reiner S.L. Role of T-bet in commitment of TH1 cells before IL-12-dependent selection. Science 292 (2001) 1907-1910
27. Novikas V., Link J., Palasik W., Söderström M., Fredrikson S., Olsson T., and Link H. Increased mRNA expression of IL-10 in mononuclear cells in multiple sclerosis and optic neuritis. Scand. J. Immunol. 41 (1995) 171-178
28. Söderström M., Link H., Sun J.B., Fredrikson S., Wang Z.Y., and Huang W.X. Autoimmune T cell repertoire in optic neuritis and multiple sclerosis: T cells recognising multiple myelin proteins are accumulated in cerebrospinal fluid. J. Neurol. Neurosurg. Psychiatry 57 (1994) 544-551
29. Staples K.J., Smallie T., Williams L.M., Foey A., Burke B., Foxwell B.M., and Ziegler-Heitbrock L. IL-10 induces IL-10 in primary human monocyte-derived macrophages via the transcription factor Stat3. J. Immunol. 178 (2007) 4779-4785
30. Stumhofer J.S., Silver J.S., Laurence A., Porrett P.M., Harris T.H., Turka L.A., Ernst M., Saris C.J., O'Shea J.J., and Hunter C.A. Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. Nat. Immunol. 8 (2007) 1363-1371
31. Wang J., Fathman J.W., Lugo-Villarino G., Scimone L., von Andrian U., Dorfman D.M., and Glimcher L.H. Transcription factor T-bet regulates inflammatory arthritis through its function in dendritic cells. J. Clin. Invest. 116 (2006) 414-421
32. Williams L.M., Sarma U., Willets K., Smallie T., Brennan F., and Foxwell B.M. Expression of constitutively active STAT3 can replicate the cytokine-suppressive activity of interleukin-10 in human primary macrophages. J. Biol. Chem. 282 (2007) 6965-6975
33. Yang X.O., Pappu B.P., Nurieva R., Akimzhanov A., Kang H.S., Chung Y., Ma L., Shah B., Panopoulos A.D., Schluns K.S., Watowich S.S., Tian Q., Jetten A.M., and Dong C. T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma. Immunity 28 (2008) 29-39